Cargando…

Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study

BACKGROUND: The effectiveness of prenatal treatment to prevent serious neurological sequelae (SNSD) of congenital toxoplasmosis is not known. METHODS AND FINDINGS: Congenital toxoplasmosis was prospectively identified by universal prenatal or neonatal screening in 14 European centres and children we...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortina-Borja, Mario, Tan, Hooi Kuan, Wallon, Martine, Paul, Malgorzata, Prusa, Andrea, Buffolano, Wilma, Malm, Gunilla, Salt, Alison, Freeman, Katherine, Petersen, Eskild, Gilbert, Ruth E.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953528/
https://www.ncbi.nlm.nih.gov/pubmed/20967235
http://dx.doi.org/10.1371/journal.pmed.1000351
_version_ 1782187857324015616
author Cortina-Borja, Mario
Tan, Hooi Kuan
Wallon, Martine
Paul, Malgorzata
Prusa, Andrea
Buffolano, Wilma
Malm, Gunilla
Salt, Alison
Freeman, Katherine
Petersen, Eskild
Gilbert, Ruth E.
author_facet Cortina-Borja, Mario
Tan, Hooi Kuan
Wallon, Martine
Paul, Malgorzata
Prusa, Andrea
Buffolano, Wilma
Malm, Gunilla
Salt, Alison
Freeman, Katherine
Petersen, Eskild
Gilbert, Ruth E.
author_sort Cortina-Borja, Mario
collection PubMed
description BACKGROUND: The effectiveness of prenatal treatment to prevent serious neurological sequelae (SNSD) of congenital toxoplasmosis is not known. METHODS AND FINDINGS: Congenital toxoplasmosis was prospectively identified by universal prenatal or neonatal screening in 14 European centres and children were followed for a median of 4 years. We evaluated determinants of postnatal death or SNSD defined by one or more of functional neurological abnormalities, severe bilateral visual impairment, or pregnancy termination for confirmed congenital toxoplasmosis. Two-thirds of the cohort received prenatal treatment (189/293; 65%). 23/293 (8%) fetuses developed SNSD of which nine were pregnancy terminations. Prenatal treatment reduced the risk of SNSD. The odds ratio for prenatal treatment, adjusted for gestational age at maternal seroconversion, was 0.24 (95% Bayesian credible intervals 0.07–0.71). This effect was robust to most sensitivity analyses. The number of infected fetuses needed to be treated to prevent one case of SNSD was three (95% Bayesian credible intervals 2–15) after maternal seroconversion at 10 weeks, and 18 (9–75) at 30 weeks of gestation. Pyrimethamine-sulphonamide treatment did not reduce SNSD compared with spiramycin alone (adjusted odds ratio 0.78, 0.21–2.95). The proportion of live-born infants with intracranial lesions detected postnatally who developed SNSD was 31.0% (17.0%–38.1%). CONCLUSION: The finding that prenatal treatment reduced the risk of SNSD in infected fetuses should be interpreted with caution because of the low number of SNSD cases and uncertainty about the timing of maternal seroconversion. As these are observational data, policy decisions about screening require further evidence from a randomized trial of prenatal screening and from cost-effectiveness analyses that take into account the incidence and prevalence of maternal infection. Please see later in the article for the Editors' Summary
format Text
id pubmed-2953528
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29535282010-10-21 Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study Cortina-Borja, Mario Tan, Hooi Kuan Wallon, Martine Paul, Malgorzata Prusa, Andrea Buffolano, Wilma Malm, Gunilla Salt, Alison Freeman, Katherine Petersen, Eskild Gilbert, Ruth E. PLoS Med Research Article BACKGROUND: The effectiveness of prenatal treatment to prevent serious neurological sequelae (SNSD) of congenital toxoplasmosis is not known. METHODS AND FINDINGS: Congenital toxoplasmosis was prospectively identified by universal prenatal or neonatal screening in 14 European centres and children were followed for a median of 4 years. We evaluated determinants of postnatal death or SNSD defined by one or more of functional neurological abnormalities, severe bilateral visual impairment, or pregnancy termination for confirmed congenital toxoplasmosis. Two-thirds of the cohort received prenatal treatment (189/293; 65%). 23/293 (8%) fetuses developed SNSD of which nine were pregnancy terminations. Prenatal treatment reduced the risk of SNSD. The odds ratio for prenatal treatment, adjusted for gestational age at maternal seroconversion, was 0.24 (95% Bayesian credible intervals 0.07–0.71). This effect was robust to most sensitivity analyses. The number of infected fetuses needed to be treated to prevent one case of SNSD was three (95% Bayesian credible intervals 2–15) after maternal seroconversion at 10 weeks, and 18 (9–75) at 30 weeks of gestation. Pyrimethamine-sulphonamide treatment did not reduce SNSD compared with spiramycin alone (adjusted odds ratio 0.78, 0.21–2.95). The proportion of live-born infants with intracranial lesions detected postnatally who developed SNSD was 31.0% (17.0%–38.1%). CONCLUSION: The finding that prenatal treatment reduced the risk of SNSD in infected fetuses should be interpreted with caution because of the low number of SNSD cases and uncertainty about the timing of maternal seroconversion. As these are observational data, policy decisions about screening require further evidence from a randomized trial of prenatal screening and from cost-effectiveness analyses that take into account the incidence and prevalence of maternal infection. Please see later in the article for the Editors' Summary Public Library of Science 2010-10-12 /pmc/articles/PMC2953528/ /pubmed/20967235 http://dx.doi.org/10.1371/journal.pmed.1000351 Text en Cortina-Borja et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Cortina-Borja, Mario
Tan, Hooi Kuan
Wallon, Martine
Paul, Malgorzata
Prusa, Andrea
Buffolano, Wilma
Malm, Gunilla
Salt, Alison
Freeman, Katherine
Petersen, Eskild
Gilbert, Ruth E.
Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study
title Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study
title_full Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study
title_fullStr Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study
title_full_unstemmed Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study
title_short Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study
title_sort prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953528/
https://www.ncbi.nlm.nih.gov/pubmed/20967235
http://dx.doi.org/10.1371/journal.pmed.1000351
work_keys_str_mv AT cortinaborjamario prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT tanhooikuan prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT wallonmartine prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT paulmalgorzata prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT prusaandrea prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT buffolanowilma prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT malmgunilla prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT saltalison prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT freemankatherine prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT peterseneskild prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT gilbertruthe prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy
AT prenataltreatmentforseriousneurologicalsequelaeofcongenitaltoxoplasmosisanobservationalprospectivecohortstudy